Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the provider of real-world applications for AI Eye Screening™, announced that it has successfully fulfilled the contract awarded by Public Health England (PHE) to use Eyenuk´s EyeArt AI Eye Screening System to grade 60,000 patient image sets from 6 different National Health Service (NHS) Diabetic Eye Screening Programmes in England, the company said.
Diabetic retinopathy (DR) is a vision-threatening complication of diabetes and a cause of preventable vision loss globally.1 In England, an estimated 4.6 million are living with diabetes, one-third of whom are at risk of developing DR. Diabetes has become a growing health concern as the number of people diagnosed with diabetes in the UK has more than doubled in the last 20 years.2
Public Health England (PHE) is an executive agency of the Department of Health and Social Care (DH) that oversees the NHS national health screening programmes. An independent Health Technology Assessment from the Moorfields Eye Hospital to determine the screening performance and cost-effectiveness of multiple DR detection AI solutions was conducted and published in 2016.6 Subsequently, PHE initiated a tender process seeking to commission an automated retinal image grading software to grade 60,000 patient image sets from multiple diabetic eye screening programmes.
The EyeArt AI Eye Screening System provides fully automated DR screening, including retinal imaging, DR grading on international standards and the option of immediate reporting, during a diabetic patient´s regular office visit. Once the patient´s fundus images have been captured and submitted to the EyeArt AI System, the DR screening results are available in a PDF report in less than 60 seconds.
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the provider of real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance.